Receive our newsletter – data, insights and analysis delivered to you
June 11, 2009

FDA Votes Zyprexa Safe for Teens

The US FDA Psychopharmacologic Drugs Advisory Committee has voted Eli Lilly’s Zyprexa (olanzapine) safe for use for adolescents suffering from bipolar I disorder and related episodes. The FDA ruled that Zyprexa, an atypical antipsychotic, is effective and acceptably safe for the acute tre

By cms admin

The US FDA Psychopharmacologic Drugs Advisory Committee has voted Eli Lilly’s Zyprexa (olanzapine) safe for use for adolescents suffering from bipolar I disorder and related episodes.

The FDA ruled that Zyprexa, an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed episodes associated with bipolar I disorder in 13 to 17-year-olds.

Lilly Research vice-president John Hayes said the FDA committee’s vote was an important step toward providing help and hope to the many teens suffering from severe mental illness.

The committee examined results from two pivotal clinical trials of Zyprexa in adolescents with schizophrenia or bipolar I disorder including a six-week double-blind, placebo-controlled trial.

The six-week trial assessed the efficacy and safety of Zyprexa in 72 adolescents with schizophrenia.

A further three-week, randomised, double-blind, placebo-controlled trial assessed the efficacy and safety of Zyprexa in 107 adolescents with acute manic or mixed episodes associated with bipolar I disorder.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

In these studies, adolescents taking Zyprexa experienced significant improvements in their schizophrenia and bipolar symptoms on various efficacy measures.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU